Skip to main content

Table 5 Predictors for Progression Free Survival (n = 174)

From: The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes

Variable Univariate Cox model Multivariate Cox model
  HR 95 % CI p-value HR 95 % CI p-value
Age at surgery 1.01 0.98–1.04 0.713 1.01 0.98–1.04 0.428
Sex       
 Male Reference    Reference   
 Female 1.38 0.83–2.3 0.218 1.46 0.85–2.51 0.170
Stage       
 Stage I Reference    Reference   
 Stage II + III 1.36 0.82–2.26 0.234 1.26 0.75–2.12 0.389
Histology       
 Adenocarcinoma Reference    Reference   
 Squamous cell carcinoma 0.94 0.50–1.78 0.850 1.06 0.55–2.07 0.856
 Other 1.08 0.56–2.09 0.814 1.30 0.65–2.59 0.458
Chemotherapy       
 Chemotherapy Reference      
 No chemotherapy 1.26 0.72–2.18 0.421    
Smoking status       
 Current Reference      
 Former 1.22 0.71–2.09 0.478    
 Never 1.33 0.52–3.40 0.557    
Tumor size       
  ≤ 3 cm Reference      
  > 3 cm - ≤ 5 cm 1.67 0.97–2.89 0.064    
  > 5 cm 1.13 0.50–2.57 0.776    
EGFR status       
 EGFR not mutated Reference      
 EGFR mutated 0.93 0.37–2.33 0.876    
Weight loss       
 No weight loss Reference      
  < 10 % 1.28 0.70–2.39 0.422    
  ≥ 10 % 1.70 0.74–3.93 0.214    
MYCN       
   < median expression Reference      
   > median expression 1.78 1.05–3.02 0.032* 1.90 1.11–3.26 0.020*
HMGA2       
   < median expression Reference      
   > median expression 1.18 0.66–2.11 0.588    
CDKN2A       
   < median expression Reference      
  > median expression 1.37 0.81–2.29 0.239    
DICER1       
   < median expression Reference      
   > median expression 1.02 0.61–1.72 0.943    
  1. mRNA expression data represented in the analysis as dichotomous variables (fold change). *p-value < 0.05